139 related articles for article (PubMed ID: 28675123)
1. ADAM9 expression promotes an aggressive lung adenocarcinoma phenotype.
Kossmann CM; Annereau M; Thomas-Schoemann A; Nicco-Overney C; Chéreau C; Batteux F; Alexandre J; Lemare F
Tumour Biol; 2017 Jul; 39(7):1010428317716077. PubMed ID: 28675123
[TBL] [Abstract][Full Text] [Related]
2. ADAM9 promotes lung cancer progression through vascular remodeling by VEGFA, ANGPT2, and PLAT.
Lin CY; Cho CF; Bai ST; Liu JP; Kuo TT; Wang LJ; Lin YS; Lin CC; Lai LC; Lu TP; Hsieh CY; Chu CN; Cheng DC; Sher YP
Sci Rep; 2017 Nov; 7(1):15108. PubMed ID: 29118335
[TBL] [Abstract][Full Text] [Related]
3. ADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinoma.
Oria VO; Lopatta P; Schmitz T; Preca BT; Nyström A; Conrad C; Bartsch JW; Kulemann B; Hoeppner J; Maurer J; Bronsert P; Schilling O
Mol Oncol; 2019 Feb; 13(2):456-479. PubMed ID: 30556643
[TBL] [Abstract][Full Text] [Related]
4. RNAi-mediated A disintegrin and metalloproteinase 9 gene silencing inhibits the tumor growth of non-small lung cancer in vitro and in vivo.
Chang L; Gong F; Cui Y
Mol Med Rep; 2015 Jul; 12(1):1197-204. PubMed ID: 25778452
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis.
Shintani Y; Higashiyama S; Ohta M; Hirabayashi H; Yamamoto S; Yoshimasu T; Matsuda H; Matsuura N
Cancer Res; 2004 Jun; 64(12):4190-6. PubMed ID: 15205330
[TBL] [Abstract][Full Text] [Related]
6. Identification of theranostic factors for patients developing metastasis after surgery for early-stage lung adenocarcinoma.
Cheng WC; Chang CY; Lo CC; Hsieh CY; Kuo TT; Tseng GC; Wong SC; Chiang SF; Huang KC; Lai LC; Lu TP; Chao KSC; Sher YP
Theranostics; 2021; 11(8):3661-3675. PubMed ID: 33664854
[No Abstract] [Full Text] [Related]
7. microRNA-590 suppresses the tumorigenesis and invasiveness of non-small cell lung cancer cells by targeting ADAM9.
Wang FF; Wang S; Xue WH; Cheng JL
Mol Cell Biochem; 2016 Dec; 423(1-2):29-37. PubMed ID: 27770372
[TBL] [Abstract][Full Text] [Related]
8. ADAM9 up-regulates N-cadherin via miR-218 suppression in lung adenocarcinoma cells.
Sher YP; Wang LJ; Chuang LL; Tsai MH; Kuo TT; Huang CC; Chuang EY; Lai LC
PLoS One; 2014; 9(4):e94065. PubMed ID: 24705471
[TBL] [Abstract][Full Text] [Related]
9. ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway.
Lin CY; Chen HJ; Huang CC; Lai LC; Lu TP; Tseng GC; Kuo TT; Kuok QY; Hsu JL; Sung SY; Hung MC; Sher YP
Cancer Res; 2014 Sep; 74(18):5229-43. PubMed ID: 25060522
[TBL] [Abstract][Full Text] [Related]
10. α1-antitrypsin promotes lung adenocarcinoma metastasis through upregulating fibronectin expression.
Li Y; Miao L; Yu M; Shi M; Wang Y; Yang J; Xiao Y; Cai H
Int J Oncol; 2017 Jun; 50(6):1955-1964. PubMed ID: 28440399
[TBL] [Abstract][Full Text] [Related]
11. Oxidative stress induces ADAM9 protein expression in human prostate cancer cells.
Sung SY; Kubo H; Shigemura K; Arnold RS; Logani S; Wang R; Konaka H; Nakagawa M; Mousses S; Amin M; Anderson C; Johnstone P; Petros JA; Marshall FF; Zhau HE; Chung LW
Cancer Res; 2006 Oct; 66(19):9519-26. PubMed ID: 17018608
[TBL] [Abstract][Full Text] [Related]
12. ADAM9 enhances CDCP1 by inhibiting miR-1 through EGFR signaling activation in lung cancer metastasis.
Chiu KL; Lin YS; Kuo TT; Lo CC; Huang YK; Chang HF; Chuang EY; Lin CC; Cheng WC; Liu YN; Lai LC; Sher YP
Oncotarget; 2017 Jul; 8(29):47365-47378. PubMed ID: 28537886
[TBL] [Abstract][Full Text] [Related]
13. The effect of disintegrin-metalloproteinase ADAM9 in gastric cancer progression.
Kim JM; Jeung HC; Rha SY; Yu EJ; Kim TS; Shin YK; Zhang X; Park KH; Park SW; Chung HC; Powis G
Mol Cancer Ther; 2014 Dec; 13(12):3074-85. PubMed ID: 25344581
[TBL] [Abstract][Full Text] [Related]
14. ADAM9 enhances CDCP1 protein expression by suppressing miR-218 for lung tumor metastasis.
Chiu KL; Kuo TT; Kuok QY; Lin YS; Hua CH; Lin CY; Su PY; Lai LC; Sher YP
Sci Rep; 2015 Nov; 5():16426. PubMed ID: 26553452
[TBL] [Abstract][Full Text] [Related]
15. ADAM9 functions as a promoter of gastric cancer growth which is negatively and post-transcriptionally regulated by miR-126.
Wang J; Zhou Y; Fei X; Chen X; Yan J; Liu B; Zhu Z
Oncol Rep; 2017 Apr; 37(4):2033-2040. PubMed ID: 28260063
[TBL] [Abstract][Full Text] [Related]
16. Tumor invasion induced by oxidative stress is dependent on membrane ADAM 9 protein and its secreted form.
Mongaret C; Alexandre J; Thomas-Schoemann A; Bermudez E; Chéreau C; Nicco C; Goldwasser F; Weill B; Batteux F; Lemare F
Int J Cancer; 2011 Aug; 129(4):791-8. PubMed ID: 21064090
[TBL] [Abstract][Full Text] [Related]
17. The pleiotropic roles of ADAM9 in the biology of solid tumors.
Oria VO; Lopatta P; Schilling O
Cell Mol Life Sci; 2018 Jul; 75(13):2291-2301. PubMed ID: 29550974
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-126 inhibits invasion in bladder cancer via regulation of ADAM9.
Jia AY; Castillo-Martin M; Bonal DM; Sánchez-Carbayo M; Silva JM; Cordon-Cardo C
Br J Cancer; 2014 Jun; 110(12):2945-54. PubMed ID: 24823697
[TBL] [Abstract][Full Text] [Related]
19. Loss of tumor suppressor miR-126 contributes to the development of hepatitis B virus-related hepatocellular carcinoma metastasis through the upregulation of ADAM9.
Xiang LY; Ou HH; Liu XC; Chen ZJ; Li XH; Huang Y; Yang DH
Tumour Biol; 2017 Jun; 39(6):1010428317709128. PubMed ID: 28639884
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of Mortalin correlates with roles in epithelial-mesenchymal transition and angiogenesis in lung adenocarcinoma.
Meng Z; Zhang R; Wu X; Zhang M; Zhang S; Jin T
Carcinogenesis; 2022 Feb; 43(1):40-51. PubMed ID: 34490878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
